A Phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract

  

Authors:	Rathkopf, D. E.; Slovin, S. F.; Autio, K. A.; Delacruz, A.; Shelkey, G.; Pisano, K.; Hullings, M.; DeNunzio, M.; Morris, M. J.; Scher, H. I.
Abstract Title:	A Phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration-resistant prostate cancer (mCRPC)
Meeting Title:	52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	34
Issue:	15 Suppl.
Meeting Dates:	2016 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2016-05-20
Language:	English
ACCESSION:	WOS:000404711501096
DOI:	10.1200/JCO.2016.34.15_suppl.e16529
PROVIDER:	wos
Notes:	Meeting Abstract: e16529 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/155071